BACKGROUND: Wenxin Keli is a Chinese herb extract reported to be of benefit in the treatment of cardiac arrhythmias, cardiac inflammation, and heart failure. METHODS AND RESULTS: We evaluated the electrophysiologic effects of Wenxin Keli in isolated canine arterially perfused right atrial preparations with a rim of right ventricular tissue (n = 11). Transmembrane action potentials and a pseudoelectrocardiogram were simultaneously recorded. Acetylcholine (1 μM) was used to induce atrial fibrillation (AF) and to test the anti-AF potential of Wenxin Keli (5 g/L). Wenxin Keli produced preferential abbreviation of action potential duration measured at 90% repolarization (APD(90)) in atria, but caused atrial-selective prolongation of the effective refractory period, due to the development of postrepolarization refractoriness. The maximum rate of rise of the action potential upstroke was preferentially reduced in atria. The diastolic threshold of excitation increased in both atria and ventricles, but much more in atria. The duration of the "P wave" (index of atrial conduction time) was prolonged to a much greater extent than the duration of the "QRS complex" (index of ventricular conduction time). Wenxin Keli significantly reduced I(Na) and shifted steady-state inactivation to more negative potentials in HEK293 cells stably expressing SCN5A. Wenxin Keli prevented the induction of persistent AF in 100% atria (6/6) and, in another experimental series, was found to terminate persistent acetylcholine-mediated AF in 100% of atria (3/3). CONCLUSION: Wenxin Keli produces atrial-selective depression of I(Na)-dependent parameters in canine isolated coronary-perfused preparations via a unique mechanism and is effective in suppressing AF and preventing its induction, with minimal effects on the ventricular electrophysiology.
BACKGROUND: Wenxin Keli is a Chinese herb extract reported to be of benefit in the treatment of cardiac arrhythmias, cardiac inflammation, and heart failure. METHODS AND RESULTS: We evaluated the electrophysiologic effects of Wenxin Keli in isolated canine arterially perfused right atrial preparations with a rim of right ventricular tissue (n = 11). Transmembrane action potentials and a pseudoelectrocardiogram were simultaneously recorded. Acetylcholine (1 μM) was used to induce atrial fibrillation (AF) and to test the anti-AF potential of Wenxin Keli (5 g/L). Wenxin Keli produced preferential abbreviation of action potential duration measured at 90% repolarization (APD(90)) in atria, but caused atrial-selective prolongation of the effective refractory period, due to the development of postrepolarization refractoriness. The maximum rate of rise of the action potential upstroke was preferentially reduced in atria. The diastolic threshold of excitation increased in both atria and ventricles, but much more in atria. The duration of the "P wave" (index of atrial conduction time) was prolonged to a much greater extent than the duration of the "QRS complex" (index of ventricular conduction time). Wenxin Keli significantly reduced I(Na) and shifted steady-state inactivation to more negative potentials in HEK293 cells stably expressing SCN5A. Wenxin Keli prevented the induction of persistent AF in 100% atria (6/6) and, in another experimental series, was found to terminate persistent acetylcholine-mediated AF in 100% of atria (3/3). CONCLUSION: Wenxin Keli produces atrial-selective depression of I(Na)-dependent parameters in canine isolated coronary-perfused preparations via a unique mechanism and is effective in suppressing AF and preventing its induction, with minimal effects on the ventricular electrophysiology.
Authors: Sandeep V Pandit; Sharon Zlochiver; David Filgueiras-Rama; Sergey Mironov; Masatoshi Yamazaki; Steven R Ennis; Sami F Noujaim; Antony J Workman; Omer Berenfeld; Jerome Kalifa; José Jalife Journal: Cardiovasc Res Date: 2010-11-13 Impact factor: 10.787
Authors: Dan Hu; Sami Viskin; Antonio Oliva; Tabitha Carrier; Jonathan M Cordeiro; Hector Barajas-Martinez; Yuesheng Wu; Elena Burashnikov; Serge Sicouri; Ramon Brugada; Rafael Rosso; Alejandra Guerchicoff; Guido D Pollevick; Charles Antzelevitch Journal: Heart Rhythm Date: 2007-04-10 Impact factor: 6.343
Authors: Alexander Burashnikov; Andrew C Zygmunt; Jose M Di Diego; Gunilla Linhardt; Leif Carlsson; Charles Antzelevitch Journal: J Cardiovasc Pharmacol Date: 2010-07 Impact factor: 3.105
Authors: Andrew C Zygmunt; Vladislav V Nesterenko; Sridharan Rajamani; Dan Hu; Hector Barajas-Martinez; Luiz Belardinelli; Charles Antzelevitch Journal: Am J Physiol Heart Circ Physiol Date: 2011-08-05 Impact factor: 4.733
Authors: Alexander Burashnikov; Serge Sicouri; José M Di Diego; Luiz Belardinelli; Charles Antzelevitch Journal: J Am Coll Cardiol Date: 2010-10-05 Impact factor: 24.094
Authors: Kapil Kumar; Bruce D Nearing; Marcelo Carvas; Bruno C G Nascimento; Mariana Acar; Luiz Belardinelli; Richard L Verrier Journal: J Cardiovasc Electrophysiol Date: 2009-02-27
Authors: Yoshino Minoura; Brian K Panama; Vladislav V Nesterenko; Matthew Betzenhauser; Hector Barajas-Martínez; Dan Hu; José M Di Diego; Charles Antzelevitch Journal: Heart Rhythm Date: 2013-03-14 Impact factor: 6.343